ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,644 SEK | -0.27% |
|
-1.82% | +21.50% |
| May. 16 | AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial | MT |
| May. 16 | Global markets live: Cisco, EasyJet, Roche, Netflix, Amazon... |  |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 51.56B 552B | Sales 2025 * | 55.37B 593B | Capitalization | 239B 2,560B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.62B 92.38B | Net income 2025 * | 10.3B 110B | EV / Sales 2024 * | 5.04 x |
| Net Debt 2024 * | 20.65B 221B | Net Debt 2025 * | 14.01B 150B | EV / Sales 2025 * | 4.57 x |
| P/E ratio 2024 * |
28.1
x | P/E ratio 2025 * |
23.4
x | Employees | 89,900 |
| Yield 2024 * |
2% | Yield 2025 * |
2.11% | Free-Float | 96.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
More news
| 1 day | -0.27% | ||
| 1 week | -1.82% | ||
| Current month | -1.62% | ||
| 1 month | +9.45% | ||
| 3 months | +25.68% | ||
| 6 months | +23.18% | ||
| Current year | +21.50% |
1 week
1 635.00
1 692.00
1 month
1 481.001 695.00
Current year
1 261.001 695.00
1 year
1 261.001 695.00
3 years
923.001 695.00
5 years
700.001 695.00
10 years
447.501 695.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 1,644 | -0.27% | 224,814 |
| 24-05-15 | 1,649 | -1.20% | 178,458 |
| 24-05-14 | 1,669 | -0.36% | 196,703 |
| 24-05-13 | 1,675 | -0.27% | 182,650 |
| 24-05-10 | 1,680 | +0.27% | 161,665 |
Delayed Quote Nasdaq Stockholm, May 16, 2024 at 11:29 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
154.2
USD
Average target price
167.6
USD
Spread / Average Target
+8.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.36% | 709B | |
| +30.77% | 595B | |
| -1.60% | 367B | |
| +20.07% | 334B | |
| +6.04% | 289B | |
| +9.13% | 211B | |
| -3.97% | 203B | |
| +9.27% | 171B | |
| +0.45% | 163B |
- Stock Market
- Equities
- AZN Stock
- AZN Stock
